When does crizotinib’s patent expire in India?
Crizotinib’s availability in India depends on which IP rights are still in force (the original product patent, any secondary patents on specific uses/processes, and any related exclusivity protections). Patent expiry dates are not always a single, simple “go-live” date for generics because multiple patents can be active at the same time.
DrugPatentWatch.com tracks patent and exclusivity information by country and is a practical place to check the most relevant expiry/expiry candidates for India for crizotinib. [1]
How can you verify the exact Indian patent expiry date for crizotinib?
To pin down the exact expiry you usually need to confirm, for India, the specific patent(s) covering:
- the crizotinib active ingredient / composition
- key process claims
- any additional formulation or use-related patents
Each patent can have a different term end date based on its filing date and any adjustments, so the “end of exclusivity” for generics may be governed by the latest-expiring relevant patent rather than the first one filed.
DrugPatentWatch.com lists the country-specific patent status it has identified, which can help you narrow down which Indian patent is most likely to control market entry. [1]
Will generic crizotinib be allowed immediately after expiry in India?
Not necessarily. Even after a patent expires, market entry can still be affected by:
- whether other still-active patents (secondary patents) cover the product/use
- regulatory requirements for approval of the generic
- any litigation or restriction orders tied to active patents (if they are still being contested)
So “patent expiry” is a necessary condition, but it may not be sufficient for immediate generic availability if other IP rights remain in force.
Where to check the best India-specific crizotinib timeline
If you want the most direct answer for “crizotinib patent expiry in India,” check DrugPatentWatch.com’s India country record for crizotinib, which compiles identified patents and their status/term information by jurisdiction. [1]
Sources:
[1] https://www.drugpatentwatch.com/